Abeona Therapeutics Announces Leadership Appointments with Max Colao as Chief Commercial Officer
26 juil. 2018 08h30 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, July 26, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Therapeutics Provides Clinical Update on MPS IIIA Gene Therapy Trial at the 21st Annual ASGCT Meeting
18 mai 2018 09h25 HE
|
Abeona Therapeutics Inc.
ABO-102 18-month efficacy and safety data continue to demonstrate time- and dose-dependent reductions in underlying disease pathology, including decreased CSF and urine GAGs and improved liver...
Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer
02 avr. 2018 08h15 HE
|
Abeona Therapeutics Inc.
Company strengthens management team with biopharmaceutical veteran bringing extensive commercial experience in life-threatening rare diseases Tim Miller, Ph.D. continues as president and assumes chief...
Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights
16 mars 2018 17h10 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, March 16, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and...
Record Attendance! Over 1,800 Clinical Ops Executives Attending SCOPE Summit in Orlando, FL
09 févr. 2018 15h37 HE
|
Cambridge Healthtech Institute
NEEDHAM, MA--(Marketwired - February 09, 2018) - Cambridge Healthtech Institute (CHI), a division of Cambridge Innovation Institute, announces agenda updates and special events planned for the Ninth...
Abeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical Trial
07 févr. 2018 08h45 HE
|
Abeona Therapeutics Inc.
First-in-man AAV9-based gene therapy delivered by single intravenous injection targeting central nervous system and peripheral manifestations of MPS IIIB.ABO-101 is well tolerated and demonstrates...
Abeona Enrolls First Subject in Spain in Ongoing Phase 1/2 Clinical Trial in MPS IIIA
09 nov. 2017 08h45 HE
|
Abeona Therapeutics Inc.
Company Opens European Subsidiary in Spain to Support Global Clinical DevelopmentNine subjects at global clinical sites enrolled to date with more than 2,000 days cumulative follow up assessed NEW...
Abeona Therapeutics Announces Public Offering of Common Stock
16 oct. 2017 16h01 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Oct. 16, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and...
Abeona Therapeutics and Brammer Bio Announce Collaboration for Commercial Translation of ABO-102
28 sept. 2017 08h32 HE
|
Abeona Therapeutics Inc
--Strategic alignment with Brammer Bio for commercial AAV process development, scale up and assay validation --Phillip B. Maples, Ph.D., to lead Abeona manufacturing, as VP of Therapeutics...
Clinical Informatics News Best Practices Awards Opens for Entries
13 juin 2017 13h30 HE
|
Clinical Informatics News
NEEDHAM, MA--(Marketwired - June 13, 2017) - Clinical Informatics News, the leader in reporting innovative technologies from clinical trials to medical informatics, today opened the call for entries...